Treatments & Interventions
Uramustine
substance
Fludarabine phosphate
substance
Pegaspargase
substance
Alemtuzumab
substance
Mercaptopurine
substance
Ifosfamide
substance
Fludarabine
substance
Cladribine
substance
Chlorambucil
substance
Cyclophosphamide
substance
Etoposide phosphate
substance
Ibrutinib
substance
Cyclophosphamide monohydrate
substance
Duvelisib
substance
Cyclophosphamide anhydrous
substance
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Cellular immunodeficiency
HP:0005374
Chronic lymphatic leukemia
HP:0005550
Related Conditions
Richter's syndrome(child)
Splenic lymphoma with villous lymphocytes(child)
Hairy cell leukaemia variant(child)
Lymphoma with spill(child)
Chronic lymphoid leukemia in remission(child)
Smoldering chronic lymphocytic leukemia(child)
Chronic lymphocytic leukemia genetic mutation variant(child)
B-cell chronic lymphocytic leukaemia variant(child)
B-cell prolymphocytic leukaemia(child)
Chronic lymphoid leukemia in relapse(child)
Lymphatic leukaemia(parent)
Quick Facts
- SNOMED CT
- 92814006
- UMLS CUI
- C0023434
- Fully Specified Name
- Chronic lymphoid leukemia, disease (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- HPO Phenotypes
- 2
- Known Treatments
- 15
Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.